A Phase I/II Study in Metastatic Breast Cancer Patients Infused With Stromagen and Isolated, Mobilized, Autologous Peripheral Blood CD34+ Progenitor Cells After High-Dose Chemotherapy
OBJECTIVES: I. Determine the safety of expanded mesenchymal stem cells (Stromagen) infusion
and autologous CD34+ peripheral blood stem cells transplantation after high dose
chemotherapy in women with metastatic breast cancer. II. Compare the time to neutrophil and
platelet engraftment in patients receiving different doses of Stromagen. III. Evaluate the
immune reconstitution of these patients after this therapy.
OUTLINE: This is a randomized, placebo controlled, blinded study. Patients are randomly
assigned to one of three treatment arms. All patients undergo mobilization of peripheral
blood stem cells (PBSC) using cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours
on day 1, and filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until
completion of leukapheresis. PBSC and bone marrow cells are collected and CD34 positive
cells are then selected. About 4 weeks later, patients receive high dose chemotherapy.
Cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24
hours are administered on days -7 to -4. Patients then receive placebo or one of two doses
of expanded mesenchymal stem cells (Stromagen) IV on day -1 and CD34+ selected PBSC IV over
2 hours on day 0. Patients are followed at 6 weeks and 12 weeks, than at 1 year.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Allocation: Randomized, Primary Purpose: Treatment
Philip L. McCarthy, MD
Roswell Park Cancer Institute
United States: Food and Drug Administration
|Roswell Park Cancer Institute||Buffalo, New York 14263|
|Barbara Ann Karmanos Cancer Institute||Detroit, Michigan 48201|
|Ireland Cancer Center||Cleveland, Ohio 44106-5065|